Fabrazyme confirmatory results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme plans to submit results of the principal confirmatory Phase IV study for its Fabry disease therapy Fabrazyme "for labeling purposes early next year," the firm says Sept. 9. A summary study report will be submitted in September. Fabrazyme (agalsidase beta) received accelerated approval for the orphan disease April 24, 2003. According to a preliminary analysis, of the 82 patients enrolled in the double-blind study, those receiving Fabrazyme were 53% less likely than placebo to experience a precursor disease event (p=0.058). Data will be presented at medical meetings in October, including the American Society of Nephrology. The firm is conducting another Phase IV verification study, due to FDA by April 2006...
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.